<DOC>
	<DOCNO>NCT02367456</DOCNO>
	<brief_summary>This multi center randomize ( 1:1 ) , double blind , placebo control Phase 1b/2 study design compare safety , efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) PF 04449913 placebo combine azacitidine patient previously untreated Intermediate 2 High Risk Myelodysplastic Syndrome ( MDS ) , Acute Myeloid Leukemia ( AML ) 20-30 % blast multi lineage dysplasia , Chronic Myelomonocytic Leukemia ( CMML ) . This clinical study include two component : ( ) Phase 1b safety lead ( b ) randomize Phase 2 .</brief_summary>
	<brief_title>A Combination Study PF-04449913 ( Glasdegib ) Azacitidine In 1st Line MDS , AML CMML Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patient must meet follow inclusion criterion eligible enrollment study : 1 . Morphologically confirm diagnosis one following : 1 . MDS accord WHO 2008 classification bone marrow blast &gt; = 5 % 2 . AML 2030 % BM blast multi lineage dysplasia , accord WHO 2008 classification WBC &lt; 20x109/L 3 . CMML accord WHO 2008 classification ( Appendix 1 ) BM blast 10 % 19 % WBC &lt; 13x109/L 2 . MDS patient must Intermediate 2 ( 1.5 2.0 point ) High Risk ( â‰¥2.5 point ) disease accord International Prognostic Scoring System 1997 ( IPSS ) . 3 . MDS patient must normal level vitamin B12 within institutional range normal determine within 28 day study entry . 4 . AML patient 20 30 % BM blast multi lineage dysplasia , must stable blast count per Investigator 's judgment . 5 . Clinical indication treatment azacitidine MDS , AML CMML . Patients follow may include study : 1 . Patients AML candidate standard induction chemotherapy first line treatment . 2 . Therapy relate ( secondary radiation chemotherapy ) MDS AML . 3 . Prior hypomethylating agent cytotoxic chemotherapy MDS , AML CMML ( prior immunosuppressive therapy hydroxyurea permit provided treatment stop within 8 2 week study entry , respectively ) . 4 . Previous hematopoietic stem cell transplant . 5 . Prior treatment license experimental smoothened inhibitor ( SMOi ) and/or hypomethylating agent ( HMA ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>CMML</keyword>
</DOC>